PreciseDx

PreciseDx is an AI pathology company offering quantitative cancer grading and risk tools that support pathology decision-making. The product is positioned around digital slide workflow, image analysis, and case prioritization rather than autonomous diagnosis, and pathologist review of every flagged case remains essential for clinical sign-off. Buyers should confirm lab information system integration depth, slide scanner compatibility, and validation evidence for the specific tissue types under review.

The clearest fit for PreciseDx is cancer pathology and diagnostic programs, and the product leans into quantitative cancer grading and risk scoring. One real limitation: early commercial footprint and narrow scope. Pricing is sales-led and scoped per buyer rather than posted publicly. Confirm validation depth, support coverage, and the rollout plan before signing.